GWAS meta-analysis links genetic variants to Alzheimer's neuropathological lesions in autopsy cohort

A multi-site autopsy study published in PLOS Genetics uses genome-wide association to map genetic loci associated with the physical hallmarks of Alzheimer's disease and related dementias, rather than clinical diagnosis alone.

Published · AI-drafted summary based on 1 public source
Illustration for polygenic story
Illustrative image — not from the source article.
Share

A research team including investigators from Vanderbilt University, the University of Pittsburgh, Columbia University, and the Alzheimer's Disease Genetics Consortium has published a genome-wide association study (GWAS) meta-analysis examining the genetic basis of neuropathological lesions in Alzheimer's disease and related dementias. The paper appears in PLOS Genetics.

Rather than relying on clinical diagnosis, the study analysed post-mortem brain tissue from a multi-site autopsy cohort, allowing direct assessment of hallmark lesions such as amyloid plaques, neurofibrillary tangles, Lewy bodies, and TDP-43 inclusions. This neuropathology-first approach is methodologically notable because clinical diagnosis of dementia can be imprecise, whereas autopsy data provide ground-truth characterisation of the underlying pathology.

The meta-analysis identified genetic loci associated with specific lesion types, building on the known architecture of Alzheimer's genetics while seeking to disentangle shared and distinct genetic influences on co-occurring pathologies. The Alzheimer's Disease Genetics Consortium contributed to the collaborative effort, which draws on data from multiple academic medical centres across the United States.

The findings add granularity to understanding how germline genetic variation shapes neuropathological heterogeneity in late-life dementias — a distinction that matters for research into disease mechanisms and for the interpretation of genetic associations identified in clinically defined cohorts.

Plain-language version

For patients, families, and general readers. Educational only — not medical advice.

Researchers have published a large genetic study looking at the physical changes that occur in the brains of people who had Alzheimer's disease or related dementias. Rather than asking who was diagnosed with dementia during their lifetime, the researchers examined brain tissue collected after death, looking directly at the biological hallmarks of these diseases — such as protein build-ups called amyloid plaques and tangles.

By doing this, they were able to look for genes that are linked to these specific brain changes. The study, published in the journal PLOS Genetics, involved researchers from several US universities working together using data from many different sites.

This kind of research helps scientists understand more precisely why some people develop certain patterns of brain disease and others do not. It does not offer any tests or treatments, but contributes to the scientific foundation that future research may build upon.

This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.

Sources

Read the original reporting — these are the public sources this summary draws from.

  1. Primary source Public Library of Science · 2026-06-29
    Genome wide association study meta-analysis of neuropathologic lesions of Alzheimer's disease and related dementias in a multi-site autopsy cohort

Tags

alzheimers-disease gwas neuropathology autopsy-cohort dementia-genetics neurogenetics meta-analysis
Share

About Genetic Current

Educational summaries of public genetics news

Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.

Join the Evagene Alpha Waiting List